PL3752598T3 - Kompozycja allogeniczna - Google Patents

Kompozycja allogeniczna

Info

Publication number
PL3752598T3
PL3752598T3 PL19706500.6T PL19706500T PL3752598T3 PL 3752598 T3 PL3752598 T3 PL 3752598T3 PL 19706500 T PL19706500 T PL 19706500T PL 3752598 T3 PL3752598 T3 PL 3752598T3
Authority
PL
Poland
Prior art keywords
allogenic
composition
allogenic composition
Prior art date
Application number
PL19706500.6T
Other languages
English (en)
Inventor
Mathias Gösta SVAHN
Original Assignee
Nextcell Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nextcell Pharma Ab filed Critical Nextcell Pharma Ab
Publication of PL3752598T3 publication Critical patent/PL3752598T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0668Mesenchymal stem cells from other natural sources
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0605Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
PL19706500.6T 2018-02-16 2019-02-15 Kompozycja allogeniczna PL3752598T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18157070 2018-02-16
PCT/EP2019/053859 WO2019158712A1 (en) 2018-02-16 2019-02-15 Allogeneic composition

Publications (1)

Publication Number Publication Date
PL3752598T3 true PL3752598T3 (pl) 2023-03-13

Family

ID=61231098

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19706500.6T PL3752598T3 (pl) 2018-02-16 2019-02-15 Kompozycja allogeniczna

Country Status (14)

Country Link
US (2) US20210008119A1 (pl)
EP (2) EP4130252A1 (pl)
JP (2) JP7150357B2 (pl)
KR (2) KR20260059679A (pl)
CN (1) CN111712565A (pl)
AU (1) AU2019220447B2 (pl)
CA (1) CA3090217A1 (pl)
DK (1) DK3752598T3 (pl)
ES (1) ES2935965T3 (pl)
FI (1) FI3752598T3 (pl)
HU (1) HUE060984T2 (pl)
PL (1) PL3752598T3 (pl)
PT (1) PT3752598T (pl)
WO (1) WO2019158712A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021028583A1 (en) * 2019-08-15 2021-02-18 Nextcell Pharma Ab Allogeneic composition for treatment of cns disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647871B2 (en) * 2007-03-30 2014-02-11 Escape Therapeutics, Inc. Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells
EP2581441A1 (en) * 2007-08-09 2013-04-17 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
PT2611906T (pt) * 2010-08-31 2024-04-16 Gallant Pet Inc Terapias sistémicas com células estaminais alogénicas para tratamento de doenças em gatos e cães
WO2012131618A1 (en) * 2011-03-30 2012-10-04 Stempeutics Research Private Limited A composition comprising pooled wharton's jelly derived mesenchymal stem cells and methods thereof
RS57886B1 (sr) * 2011-11-30 2019-01-31 Astellas Inst For Regenerative Medicine Mezenhimalne stromalne ćelije i primene vezane za njih
WO2015016761A2 (en) * 2013-08-01 2015-02-05 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
ES2769778T3 (es) * 2013-12-13 2020-06-29 Swedish Stromabio Ab Composiciones inmunomoduladoras
EP2975118B1 (en) * 2014-07-16 2016-08-24 Johann Wolfgang Goethe-Universität, Frankfurt am Main Generation of a mesenchymal stromal cell bank from the pooled mononuclear cells of multiple bone marrow donors
EP3250682A4 (en) * 2015-01-26 2018-08-01 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture

Also Published As

Publication number Publication date
AU2019220447B2 (en) 2024-10-03
KR20200121805A (ko) 2020-10-26
WO2019158712A1 (en) 2019-08-22
JP2021514946A (ja) 2021-06-17
DK3752598T3 (da) 2022-11-21
KR102955855B1 (ko) 2026-04-23
ES2935965T3 (es) 2023-03-13
HUE060984T2 (hu) 2023-04-28
EP3752598A1 (en) 2020-12-23
PT3752598T (pt) 2023-01-09
JP7534800B2 (ja) 2024-08-15
CA3090217A1 (en) 2019-08-22
US20250249041A1 (en) 2025-08-07
CN111712565A (zh) 2020-09-25
EP4130252A1 (en) 2023-02-08
AU2019220447A1 (en) 2020-07-30
JP2022180506A (ja) 2022-12-06
EP3752598B1 (en) 2022-11-02
JP7150357B2 (ja) 2022-10-11
KR20260059679A (ko) 2026-04-30
FI3752598T3 (fi) 2023-02-22
US20210008119A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
EP3722358A4 (en) COMPOSITION
DK3697376T3 (da) Sammensætning
EP3878518A4 (en) Flavor composition
EP3853332C0 (en) COMPOSITION
EP3878929A4 (en) LUBRICANT COMPOSITION
EP3882323A4 (en) COMPOSITION
EP3878931A4 (en) LUBRICANT COMPOSITION
EP3820926C0 (en) RADIATION-CURABLE COMPOSITION
DK3840596T3 (da) Sammensætning
LT3651736T (lt) Ilgai veikiančios kompozicijos
EP3871694A4 (en) COMPOSITION
EP3897866C0 (en) ANTIMICROBIAL COMPOSITION
EP3864058A4 (en) PHOTOCURABLE COMPOSITION
DK4234656T3 (da) Sammensætninger
EP3981256A4 (en) COMPOSITION
EP3941942A4 (en) COMPOSITION
EP3768808A4 (en) LUBRICANT COMPOSITION
PT3765379T (pt) Composições
EP3683264A4 (en) ENCAPSULATION COMPOSITION
EP3954721A4 (en) Composition
EP3914303C0 (en) VIRUCIDAL COMPOSITION
EP3741814C0 (en) COMPOSITION
EP3795663A4 (en) LUBRICANT COMPOSITION
EP3829532A4 (en) KERATIN COMPOSITIONS
EP3892256A4 (en) COSMETIC COMPOSITION